L

LUX Infusion

Outpatient infusion centers for IV therapies

Pharmacy Technician

Full-TimeUpdated on 10/23/2026
$25 - $28
Junior
Van Nuys, Los Angeles, CA, USA
In PersonOn-site in Van Nuys, CA; work location may change based on business needs.
Medical, Clinical & VeterinaryPharmacy

About the job

Requirements
  • A high school diploma or GED is required.
  • A current and valid Pharmacy Technician license in good standing, issued by the state in which duties are performed, is required.
  • At least two years of experience in retail, hospital, or specialty pharmacy is required.
  • Basic computer and internet skills, including Microsoft Office, are required.
  • Strong customer service skills, focus, and dedication are required.
  • The ability to prioritize and handle multiple tasks and projects concurrently is required.
  • Scheduling flexibility and the ability to work overtime when necessary are required.
  • Careful attention to detail is required.
  • Excellent interpersonal and organizational skills are required.
  • The ability to prioritize, multitask, and manage multiple responsibilities in a fast-paced environment is required.
  • The ability to focus on detail, be task-oriented, and commit to accuracy and risk reduction is required.
  • The ability to work cooperatively with the pharmacist and other pharmacy operations staff is required.
  • The ability to respond quickly to emergency requests is required.
  • Oral communication skills include speaking clearly and persuasively, listening, seeking clarification, responding to questions, and participating in meetings.
  • Written communication skills include writing clearly and informatively, editing for spelling and grammar, adapting writing style to needs, and reading and interpreting written information.
  • The employee must become and remain proficient in all programs necessary to execute tasks in the role.
  • Employees are expected to participate annually in required legal and ethical compliance training, comply with the organization's legal, ethical, and compliance policies, follow the Compliance Manual, and refrain from unethical or unlawful behavior.
  • Employees may be required to assist directly or coordinate assistance to ensure access to services for individuals with disabilities.
Responsibilities
  • Perform designated technical and clerical tasks associated with preparing, labeling, and dispensing medications, including sterile admixtures and prepackaged or unit-dose drugs.
  • Perform designated tasks related to pharmacy quality control, pharmacy records management, inventory control, and preparing drug orders, under the direct supervision of a pharmacist.
  • Perform all duties under the direct supervision of a pharmacist.
  • Adhere to BioMatrix policies and procedures and comply with federal, state, and local laws, rules, and regulations.
  • Comply with the HIPAA Privacy Rule and maintain strict confidentiality of patient, client, and employee information.
  • Prepare and generate batches for prescription preparation.
  • Prepare prescriptions and enter them into the CPR+ pharmacy software system for pharmacist verification, including delivery addresses, FedEx tracking numbers, changes in patient health status, and communications to the pharmacist.
  • Enter new products and supplies accurately into CPR+ and maintain appropriate drug and supply inventory levels.
  • Generate labels, pick, and package prepackaged and unit-dose drugs in accordance with dispensing orders.
  • Maintain patient files with current prescriptions.
  • Communicate with the billing department to ensure pending orders are approved and insurance clearance is obtained before shipment.
  • Notify the pharmacist of new prescriptions for subsequent patient orders.
  • Work with the intake coordinator to schedule shipment of drugs, pumps, and supplies.
  • Communicate shipment details, including items shipped, delivery address, and shipment date, to field staff and managers.
  • Process reorders in CPR+ according to RCC/PCS Order Request Forms.
  • Accept product and supply deliveries, unpack them, verify order accuracy, and forward packing information to accounts payable.
  • Monitor FedEx shipments to confirm delivery and fax delivery tickets into the system.
  • File delivery tickets, order forms, and prescriptions efficiently and promptly.
  • Perform and record quality assurance activities.
  • Maintain medication, ancillary, and supply inventory levels to company goals, rotate stock, and use the return process.
  • Ensure the pharmacy area is clean and maintained according to organizational policies and procedures.
  • Improve understanding of bleeding disorders and other chronic disorders, products, and treatments; stay current on legislative changes and insurance coverage; and share relevant information with employees, patients, and others in the bleeding disorder community.
  • Attend quarterly QMC meetings and provide input.
  • Maintain professional growth through seminars, workshops, and professional affiliations, and attend continuing education programs to stay current in pharmacy and information systems.
  • Participate in continuing education programs, maintain current knowledge of government regulations and industry best practices, and provide relevant updates to staff.
  • Perform related duties as requested.
  • Participate in quality assurance activities and audits as directed.
Desired Qualifications
  • Graduation from a pharmacy technical college is preferred.
  • National certification by the Pharmacy Technician Certification Board is preferred.
  • Knowledge of CareTend is preferred.

About the company

LUX Infusion provides ambulatory infusion services in Alaska, delivering IV and injectable therapies outside hospital settings in spa-like centers in Anchorage, Palmer, and Fairbanks. A clinical team of physicians, nurse practitioners, and infusion nurses collaborates with referring providers, while centers handle pre-authorizations and financial assistance, serving patients with private insurance, Medicare, and Medicaid. In 2025, LUX Infusion was acquired by BioMatrix Infusion Pharmacy, integrating its care teams into a national ambulatory infusion network to expand the Pacific Northwest and accelerate growth; the company holds NICA accreditation and the AICE-Ambulatory Infusion Center of Excellence designation. Its goal is to provide high-quality, patient-centered outpatient infusion care that reduces medical costs and offers an alternative to hospital-based treatment.

Company Size

1-10

Company Stage

N/A

Total Funding

N/A

Headquarters

Anchorage, Alaska

Founded

2022

Get referred to LUX Infusion

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • August 6, 2026 Infuse IQ acquisition adds Wyoming sites and widens referral reach.
  • May 28, 2026 promotion of Dan Teich strengthens market-access negotiations with payors and manufacturers.
  • Home infusion plus ambulatory care creates cross-referral opportunities and more therapy starts than hospital sites.

What critics are saying

  • Biomatrix integration can standardize LUX away, erasing local brand distinction by 2027.
  • Infuse IQ’s August 6, 2026 acquisition stretches management and capital across Wyoming and Alaska.
  • Specialty infusion reimbursement pressure from payors and manufacturers can compress margins if contracts reset in 2027.

What makes LUX Infusion unique

  • Alaska’s only scaled ambulatory infusion footprint in Anchorage, Palmer, and Fairbanks anchors local density.
  • Clinician-led, spa-like infusion centers with NICA and AICE designations signal differentiated patient experience.
  • BioMatrix acquired LUX on October 17, 2025, plugging it into national specialty-infusion infrastructure.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Remote Work Options

Company News

PR Newswire
Oct 15th, 2026
LUX Infusion enters Colorado with acquisition of Loveland-based Suite Health

LUX Infusion, a clinician-led infusion services company based in Plantation, Florida, has acquired Suite Health, a specialty infusion therapy provider in Loveland, Colorado. The deal, announced October 15, 2026, marks LUX Infusion's entry into Colorado. Suite Health's local clinical team is known for patient support and responsive referral coordination. LUX Infusion will add clinical, operational, and technological resources while keeping Suite Health's personalised approach. "Our role is to build on that foundation," said Ted Kramm, chief executive officer of LUX Infusion. He said the aim is to make it easier for more patients to access infusion care in the setting that suits them best. LUX Infusion is a portfolio company of Frazier Healthcare Partners. The source gave no financial terms.

PR Newswire
Oct 9th, 2026
LUX Infusion adds Qfitlia to hemophilia treatment portfolio, expanding access for patients 12 and older

LUX Infusion, a US-based clinician-led infusion service network, announced it is now authorised to dispense Qfitlia (fitusiran), expanding access to hemophilia treatment. The subcutaneous therapy is for patients aged 12 and older with hemophilia A or B, with or without Factor VIII or IX inhibitors, requiring routine bleed prevention treatment. The company provides comprehensive support throughout the treatment process, including benefit navigation and 24/7 on-call guidance. LUX Infusion pairs each patient with a dedicated contact who has bleeding disorder experience and works closely with Hemophilia Treatment Centers. "Adding Qfitlia to our portfolio enables us to offer a unique treatment option that is fully supported by our high-touch model," said Ted Kramm, chief executive officer of LUX Infusion.

Access Market Intelligence
Aug 30th, 2026
Specialty Pharmacy news roundup: august 2026.

Specialty Pharmacy news roundup: august 2026. The following are just a few of the many recent specialty pharmacy activities during the past month. Biologics by McKesson, an independent specialty pharmacy specializing in oncology, cell and gene, and rare disease therapies, has been selected by Cycle Pharmaceuticals as a limited distribution specialty pharmacy provider for CAVHANZA (nilotinib) Orally Disintegrating Tablets. CAVHANZA is a tyrosine kinase inhibitor indicated for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase; and/or adult patients with chronic phase (CP) and accelerated phase (AP) Ph+ CML resistant to or intolerant to prior therapy that included imatinib. Biologics by McKesson has also been selected by Revolution Medicines as a specialty pharmacy provider for RASONQUE (daraxonrasib) within its distribution network. RASONQUE is an oral therapy approved for the treatment of adult patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy. Carepoint Pharmacy, an end-to-end access hub and dispensing pharmacy serving patients nationwide, announced a new partnership with and investment from New Heritage Capital, a Boston-based private equity firm focused on partnering with high-growth, founder-owned businesses. The investment was structured using Heritage's Private IPO solution, which leaves operating control in the hands of current Carepoint management while providing the financial flexibility to accelerate future growth. LUX Infusion, a clinician-led infusion services company, announced the acquisition of Infuse IQ, a trusted Wyoming-headquartered independent infusion therapy provider delivering safe, personalized infusion and injection treatments across a broad range of medical specialties. The acquisition expands LUX Infusion's ambulatory infusion network and strengthens its ability to serve patients and referring providers in communities across the country. Onco360, the nation's leading independent Specialty Pharmacy, has been selected as a pharmacy partner by Rigel Pharmaceuticals for VEPPANU (vepdegestrant), which is indicated for the treatment of adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, estrogen receptor-1 (ESR1)-mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy. Onco360 has also been selected as a pharmacy partner by Revolution Medicines for RASONQUE (daraxonrasib), which is an inhibitor of the RAS GTPase family, indicated for the treatment of adult patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy. PANTHERx Rare has been selected by Intercept Pharmaceuticals, Inc., a wholly owned subsidiary of Alfasigma S.p.A., as the exclusive U.S. specialty pharmacy partner to distribute LYNAVOY (linerixibat), the first FDA-approved treatment specifically indicated for cholestatic pruritus in adults with primary biliary cholangitis (PBC). This collaboration underscores the company's commitment to innovative rare disease care and its mission to reduce barriers for patients facing complex conditions. PANTHERx Rare has also been selected by Vera Therapeutics, Inc. to dispense TRUTAKNA (atacicept-vymj), an FDA-approved treatment indicated to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of disease progression. IgAN is a complex, progressive kidney disease, and timely access to treatment can make a meaningful difference. The company's team is committed to helping patients navigate access, stay on therapy, and receive personalized support every step of the way. You can find even more news and insights by subscribing to AMI's Specialty Pharmacy Database. Keep up with accreditations earned, key decision-maker changes, mergers and acquisitions and MORE.

PR Newswire
Aug 6th, 2026
LUX Infusion Acquires Infuse IQ, Expanding Its National Ambulatory Infusion Footprint

/PRNewswire/ -- LUX Infusion, a clinician-led infusion services company, today announced the acquisition of Infuse IQ, a trusted Wyoming-headquartered...

LUX Infusion
May 28th, 2026
LUX Infusion promotes Dan Teich to Senior Vice President, Market Access.

LUX Infusion promotes Dan Teich to Senior Vice President, Market Access. Unified leadership role aligns trade relations and managed care to strengthen distribution, manufacturer, and payor partnerships. [Plantation, FL] - May 28, 2026 - LUX Infusion, a U.S.-based, clinician-led infusion services company, today announced the promotion of Dan Teich to Senior Vice President, Market Access. In this expanded role, Teich will lead a unified market access function that brings together the company's trade relations and managed care operations under a single, cohesive strategy designed to deepen alignment with LUX Infusion's distribution, manufacturer, and payor partners. "Dan has been an exceptional leader in shaping our trade relationships, and this promotion reflects both his contributions and our confidence in his vision," said Ted Kramm, Chief Executive Officer of LUX Infusion. "By unifying trade relations and managed care under his leadership, we are creating a more integrated approach to how we work with our partners, positioning LUX Infusion to deliver greater value across the entire specialty infusion ecosystem." As SVP, Market Access, Teich will be responsible for developing and executing a comprehensive strategy that aligns the company's market access partnerships across pharmaceutical manufacturers, specialty distributors, group purchasing organizations, and health plan payors with LUX Infusion's mission to expand patient access to high-quality, accessible infusion care. Teich brings more than 15 years of expertise in pharmacy operations, supply chain management, contract negotiation, and executive leadership across the specialty infusion, health system, and retail pharmacy sectors. Prior to joining LUX Infusion, he served as Vice President of Health Systems Manufacturer Relations at Cencora (formerly AmerisourceBergen), where he led negotiations of specialty and biosimilar GPO contracts for health systems, consistently exceeding fiscal-year performance targets. Before Cencora, Teich served as Vice President of Pharmacy Purchasing and Contracting at M Health Fairview, overseeing nearly $1 billion in annual drug spend and driving significant margin improvements through strategic contracting. As Program Manager of Home Infusion and Compounding at the same organization, he grew home infusion revenue by more than 240% over four years. He also held leadership roles at PharMerica and Walgreens. Teich holds a Doctor of Pharmacy (Pharm.D.) from North Dakota State University and has been a licensed pharmacist in Minnesota since 2007. "The convergence of trade relations and managed care under a unified market access function is a natural evolution for LUX Infusion as we scale nationally," said Teich. "I'm energized by the opportunity to work even more closely with our manufacturer, distribution, and payor partners to remove barriers and ensure patients receive the therapies they need, when and where they need them." This leadership structure reflects LUX Infusion's broader commitment to building a fully integrated infusion services platform that leverages strong partner relationships to drive superior clinical outcomes, operational efficiency, and expanded patient access as the company continues its growth toward more than 50 infusion locations nationwide. About LUX Infusion. LUX Infusion is elevating infusions into an experience. As a U.S. based, clinician-led infusion services company, it provides both home infusion and ambulatory infusion center services, bringing clarity, compassion, and expertise to every patient relationship. With faster therapy starts, dedicated patient support, and continuous data sharing with providers, LUX Infusion ensures patients feel supported, and providers and partners can trust in better adherence and outcomes. Media Contact: Tara Marchese Senior Director of Marketing, LUX Infusion Tel: 954-908-7636 Email: [email protected]